News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Delcath Systems, Inc. (DCTH) Finally Gets Good News From the FDA



10/3/2013 8:18:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The price of stock in Delcath Systems Inc. is rising sharply today, because the Queensbury, N.Y.-based pharmaceutical and medical device manufacturer finally got some good news from the U.S. Food & Drug Administration. The FDA granted Delcath (Nasdaq: DCTH) an “orphan drug” designation for melphalan hydrochloride—which it calls Melblez—in the treament of primary liver cancer. Orphan drug status is given to novel drugs that treat rare diseases or conditions affecting fewer than 200,000 patients in the United States.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES